Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a corrected disclosure revising its FY2025 consolidated revenue guidance upward from KRW 5.5705T (midpoint of +20% to +25% YoY growth range) to KRW 5.7978T (midpoint of +25% to +30% YoY growth range).
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Forecast of Operating Results Based on Consolidated Financial Statements (Fair Disclosure) (Submitted on January 22, 2025)
- Reason for Correction: Upward revision of revenue forecast
- Key Correction Items for FY2025 Consolidated Performance Guidance (KRW 100M):
- Revenue Guidance: (Before) KRW 55,705 hundred million → (After) KRW 57,978 hundred million (approx. KRW 5.7978T)
- Basis for Guidance (Midpoint of Forecasted Revenue Range):
- (Before) Midpoint of +20% to +25% YoY growth range
- (After) Midpoint of +25% to +30% YoY growth range
- Target Period: January 1, 2025 – December 31, 2025
- Basis for Outlook: Market outlook and business plan
- Information Provision Details:
- Provider: IR Team
- Target Audience: Domestic and international investors, etc.
- Date & Time: July 23, 2025
- Historical Accuracy (FY2024 Performance vs. Guidance):
- FY2024 Revenue: Forecasted KRW 43,411 hundred million / Actual KRW 45,473 hundred million (Error Rate: 4.7%)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Progress Toward Upwardly Revised FY2025 Revenue Guidance
This correction disclosure reflects an upward revision of the company’s FY2025 revenue guidance and midpoint growth range (+25% to +30% YoY).
Tracking whether the revised revenue guidance of KRW 5.7978T is realized through upcoming quarterly and annual financial filings is essential.
Relevant developments can be verified in subsequent quarterly operating results disclosures and periodic financial reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
